Ann: Further Significant Improvement in Rett Syndrome Patients, page-4

Looks pretty solid to me @ma420

Rett Syndrome Patients Show Further Clinical
Improvement After 20 Weeks of NTI164 Treatment
Key Points:
• Further significant clinical improvements observed in Rett Syndrome patients after 20 weeks of daily
oral treatment with Neurotech’s broad-spectrum cannabinoid drug therapy NTI164

• Continued clinical improvement at 20 weeks (versus baseline) on four core Rett-domain anchors
with 100% of patients (pts) improved (p<0.001) vs. 93% at wk 12 with 57% of pts “very much/much
improved” (vs. 36% at wk 12)

• Gold standard RSBQ measure of key Rett symptoms showed an improvement of 24% versus baseline
(p<0.001), with no further improvement from week 12 to week 20 (p=0.08)
• No diarrhoea, vomiting/nausea reported from 12 to 20 weeks and no weight loss with all 14 pts who
commenced the Phase I/II clinical trial remaining on treatment

• Durable clinical response, coupled with excellent safety provides strong rationale for long term
administration of NTI164 for Rett Syndrome patients where new treatments are urgently required